Development and Progression of Polyneuropathy Over 5 Years in Patients With Type 2 Diabetes
There is a need for knowledge regarding the natural course of diabetic polyneuropathy (DPN), a complication in type 2 diabetes (T2D). The aim of this study was to examine the development of DPN over time. Patients with newly diagnosed T2D, recruited from a national cohort, and controls without diabe...
Gespeichert in:
Veröffentlicht in: | Neurology 2024-08, Vol.103 (3), p.e209652 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 3 |
container_start_page | e209652 |
container_title | Neurology |
container_volume | 103 |
creator | Brask-Thomsen, Peter Kolind Itani, Mustapha Karlsson, Pall Kristensen, Alexander G Krøigård, Thomas Jensen, Troels S Tankisi, Hatice Sindrup, Søren H Finnerup, Nanna B Gylfadottir, Sandra Sif |
description | There is a need for knowledge regarding the natural course of diabetic polyneuropathy (DPN), a complication in type 2 diabetes (T2D). The aim of this study was to examine the development of DPN over time.
Patients with newly diagnosed T2D, recruited from a national cohort, and controls without diabetes of similar age and sex, underwent sensory phenotyping in 2016-2018. The Toronto consensus criteria were used to classify patients into possible, probable, and confirmed DPN. For this 5-year, observational, follow-up, cohort study, all participants were invited to a reexamination combining bedside sensory examination, quantitative sensory testing (QST), nerve conduction studies (NCSs), and skin biopsies measuring intraepidermal nerve fiber density (IENFD) in order to compare phenotypic and diagnostic changes over time.
Of the baseline 389 patients and 97 controls, 184 patients (median [interquartile range] diabetes duration 5.9 [4.1-7.4] years, mean hemoglobin A1c [HbA1c] 51 ± 11 mmol/mol at baseline) and 43 controls completed follow-up (46.9%). Confirmed DPN was present in 35.8% and 50.3%, probable DPN in 27.2% and 14.6%, possible DPN in 17.2% and 16.6%, and no DPN in 15.2% and 17.9% at baseline and follow-up, respectively. The estimated prevalence (95% CI) of confirmed DPN was 33.5% (24.9-42.1) compared with 22.7% (17.5-28.0) at baseline. During the follow-up period, 43.9% of patients with probable DPN developed confirmed DPN. Progression of neuropathy occurred in 16.5% and 24.7% and regression in 5.9% and 18.6% of patients based on NCS and IENFD, respectively. Progression based on NCS and/or IENFD was associated with higher baseline waist circumference and triglycerides, and regression with lower baseline HbA1c. Patients with at least probable DPN at baseline but neither patients without DPN nor controls developed increased spread of hyposensitivity, more hyposensitivity on QST and lower NCS
-scores at follow-up, and worsening of nerve parameters at follow-up correlated with higher baseline triglycerides.
In patients with well-regulated T2D, the proportion of patients with confirmed DPN increased over 5 years driven by progression from probable DPN. A large proportion of patients progressed, and a smaller proportion regressed on nerve parameters. Higher triglycerides correlated with this progression and may constitute a risk factor. |
doi_str_mv | 10.1212/WNL.0000000000209652 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3081289505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3081289505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c186t-c69401bcad54f1ac95d5e8decb936a3bca78752d11cc8c2677d288eb3ce00ee13</originalsourceid><addsrcrecordid>eNpdkM1OwzAQhC0EoqXwBgj5yCVlbdeJc0Qtf1JFeygqiEPkOBsalMbBTirl7Qkq9MBeVtqZ2ZE-Qi4ZjBln_Gb9PB_DYTjEoeRHZMgkD4NQ8NdjMuzPKhAqUgNy5v0nQC9G8SkZiBhAKYAheZ_hDktbb7FqqK4yunT2w6H3ha2ozenSll2FrbO1bjYdXezQUUnfUDtPi4oudVP0SU_XRbOhq65Gyums0Ck26M_JSa5Ljxe_e0Re7u9W08dgvnh4mt7OA8NU2AQmjCfAUqMzOcmZNrHMJKoMTRqLUIteiFQkecaYMcrwMIoyrhSmwiAAIhMjcr3_Wzv71aJvkm3hDZalrtC2PhGgGFexBNlbJ3urcdZ7h3lSu2KrXZcwSH6wJj3W5D_WPnb129CmW8wOoT-O4hs9VnNs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3081289505</pqid></control><display><type>article</type><title>Development and Progression of Polyneuropathy Over 5 Years in Patients With Type 2 Diabetes</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>Brask-Thomsen, Peter Kolind ; Itani, Mustapha ; Karlsson, Pall ; Kristensen, Alexander G ; Krøigård, Thomas ; Jensen, Troels S ; Tankisi, Hatice ; Sindrup, Søren H ; Finnerup, Nanna B ; Gylfadottir, Sandra Sif</creator><creatorcontrib>Brask-Thomsen, Peter Kolind ; Itani, Mustapha ; Karlsson, Pall ; Kristensen, Alexander G ; Krøigård, Thomas ; Jensen, Troels S ; Tankisi, Hatice ; Sindrup, Søren H ; Finnerup, Nanna B ; Gylfadottir, Sandra Sif</creatorcontrib><description>There is a need for knowledge regarding the natural course of diabetic polyneuropathy (DPN), a complication in type 2 diabetes (T2D). The aim of this study was to examine the development of DPN over time.
Patients with newly diagnosed T2D, recruited from a national cohort, and controls without diabetes of similar age and sex, underwent sensory phenotyping in 2016-2018. The Toronto consensus criteria were used to classify patients into possible, probable, and confirmed DPN. For this 5-year, observational, follow-up, cohort study, all participants were invited to a reexamination combining bedside sensory examination, quantitative sensory testing (QST), nerve conduction studies (NCSs), and skin biopsies measuring intraepidermal nerve fiber density (IENFD) in order to compare phenotypic and diagnostic changes over time.
Of the baseline 389 patients and 97 controls, 184 patients (median [interquartile range] diabetes duration 5.9 [4.1-7.4] years, mean hemoglobin A1c [HbA1c] 51 ± 11 mmol/mol at baseline) and 43 controls completed follow-up (46.9%). Confirmed DPN was present in 35.8% and 50.3%, probable DPN in 27.2% and 14.6%, possible DPN in 17.2% and 16.6%, and no DPN in 15.2% and 17.9% at baseline and follow-up, respectively. The estimated prevalence (95% CI) of confirmed DPN was 33.5% (24.9-42.1) compared with 22.7% (17.5-28.0) at baseline. During the follow-up period, 43.9% of patients with probable DPN developed confirmed DPN. Progression of neuropathy occurred in 16.5% and 24.7% and regression in 5.9% and 18.6% of patients based on NCS and IENFD, respectively. Progression based on NCS and/or IENFD was associated with higher baseline waist circumference and triglycerides, and regression with lower baseline HbA1c. Patients with at least probable DPN at baseline but neither patients without DPN nor controls developed increased spread of hyposensitivity, more hyposensitivity on QST and lower NCS
-scores at follow-up, and worsening of nerve parameters at follow-up correlated with higher baseline triglycerides.
In patients with well-regulated T2D, the proportion of patients with confirmed DPN increased over 5 years driven by progression from probable DPN. A large proportion of patients progressed, and a smaller proportion regressed on nerve parameters. Higher triglycerides correlated with this progression and may constitute a risk factor.</description><identifier>ISSN: 0028-3878</identifier><identifier>ISSN: 1526-632X</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000209652</identifier><identifier>PMID: 39008800</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Cohort Studies ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - epidemiology ; Diabetic Neuropathies - epidemiology ; Diabetic Neuropathies - pathology ; Disease Progression ; Female ; Follow-Up Studies ; Glycated Hemoglobin - metabolism ; Humans ; Male ; Middle Aged ; Neural Conduction - physiology</subject><ispartof>Neurology, 2024-08, Vol.103 (3), p.e209652</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c186t-c69401bcad54f1ac95d5e8decb936a3bca78752d11cc8c2677d288eb3ce00ee13</cites><orcidid>0000-0003-0357-8628 ; 0000-0002-8323-1394 ; 0000-0001-7082-9576 ; 0000-0002-3487-6380</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39008800$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brask-Thomsen, Peter Kolind</creatorcontrib><creatorcontrib>Itani, Mustapha</creatorcontrib><creatorcontrib>Karlsson, Pall</creatorcontrib><creatorcontrib>Kristensen, Alexander G</creatorcontrib><creatorcontrib>Krøigård, Thomas</creatorcontrib><creatorcontrib>Jensen, Troels S</creatorcontrib><creatorcontrib>Tankisi, Hatice</creatorcontrib><creatorcontrib>Sindrup, Søren H</creatorcontrib><creatorcontrib>Finnerup, Nanna B</creatorcontrib><creatorcontrib>Gylfadottir, Sandra Sif</creatorcontrib><title>Development and Progression of Polyneuropathy Over 5 Years in Patients With Type 2 Diabetes</title><title>Neurology</title><addtitle>Neurology</addtitle><description>There is a need for knowledge regarding the natural course of diabetic polyneuropathy (DPN), a complication in type 2 diabetes (T2D). The aim of this study was to examine the development of DPN over time.
Patients with newly diagnosed T2D, recruited from a national cohort, and controls without diabetes of similar age and sex, underwent sensory phenotyping in 2016-2018. The Toronto consensus criteria were used to classify patients into possible, probable, and confirmed DPN. For this 5-year, observational, follow-up, cohort study, all participants were invited to a reexamination combining bedside sensory examination, quantitative sensory testing (QST), nerve conduction studies (NCSs), and skin biopsies measuring intraepidermal nerve fiber density (IENFD) in order to compare phenotypic and diagnostic changes over time.
Of the baseline 389 patients and 97 controls, 184 patients (median [interquartile range] diabetes duration 5.9 [4.1-7.4] years, mean hemoglobin A1c [HbA1c] 51 ± 11 mmol/mol at baseline) and 43 controls completed follow-up (46.9%). Confirmed DPN was present in 35.8% and 50.3%, probable DPN in 27.2% and 14.6%, possible DPN in 17.2% and 16.6%, and no DPN in 15.2% and 17.9% at baseline and follow-up, respectively. The estimated prevalence (95% CI) of confirmed DPN was 33.5% (24.9-42.1) compared with 22.7% (17.5-28.0) at baseline. During the follow-up period, 43.9% of patients with probable DPN developed confirmed DPN. Progression of neuropathy occurred in 16.5% and 24.7% and regression in 5.9% and 18.6% of patients based on NCS and IENFD, respectively. Progression based on NCS and/or IENFD was associated with higher baseline waist circumference and triglycerides, and regression with lower baseline HbA1c. Patients with at least probable DPN at baseline but neither patients without DPN nor controls developed increased spread of hyposensitivity, more hyposensitivity on QST and lower NCS
-scores at follow-up, and worsening of nerve parameters at follow-up correlated with higher baseline triglycerides.
In patients with well-regulated T2D, the proportion of patients with confirmed DPN increased over 5 years driven by progression from probable DPN. A large proportion of patients progressed, and a smaller proportion regressed on nerve parameters. Higher triglycerides correlated with this progression and may constitute a risk factor.</description><subject>Aged</subject><subject>Cohort Studies</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Diabetic Neuropathies - epidemiology</subject><subject>Diabetic Neuropathies - pathology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glycated Hemoglobin - metabolism</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neural Conduction - physiology</subject><issn>0028-3878</issn><issn>1526-632X</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkM1OwzAQhC0EoqXwBgj5yCVlbdeJc0Qtf1JFeygqiEPkOBsalMbBTirl7Qkq9MBeVtqZ2ZE-Qi4ZjBln_Gb9PB_DYTjEoeRHZMgkD4NQ8NdjMuzPKhAqUgNy5v0nQC9G8SkZiBhAKYAheZ_hDktbb7FqqK4yunT2w6H3ha2ozenSll2FrbO1bjYdXezQUUnfUDtPi4oudVP0SU_XRbOhq65Gyums0Ck26M_JSa5Ljxe_e0Re7u9W08dgvnh4mt7OA8NU2AQmjCfAUqMzOcmZNrHMJKoMTRqLUIteiFQkecaYMcrwMIoyrhSmwiAAIhMjcr3_Wzv71aJvkm3hDZalrtC2PhGgGFexBNlbJ3urcdZ7h3lSu2KrXZcwSH6wJj3W5D_WPnb129CmW8wOoT-O4hs9VnNs</recordid><startdate>20240813</startdate><enddate>20240813</enddate><creator>Brask-Thomsen, Peter Kolind</creator><creator>Itani, Mustapha</creator><creator>Karlsson, Pall</creator><creator>Kristensen, Alexander G</creator><creator>Krøigård, Thomas</creator><creator>Jensen, Troels S</creator><creator>Tankisi, Hatice</creator><creator>Sindrup, Søren H</creator><creator>Finnerup, Nanna B</creator><creator>Gylfadottir, Sandra Sif</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0357-8628</orcidid><orcidid>https://orcid.org/0000-0002-8323-1394</orcidid><orcidid>https://orcid.org/0000-0001-7082-9576</orcidid><orcidid>https://orcid.org/0000-0002-3487-6380</orcidid></search><sort><creationdate>20240813</creationdate><title>Development and Progression of Polyneuropathy Over 5 Years in Patients With Type 2 Diabetes</title><author>Brask-Thomsen, Peter Kolind ; Itani, Mustapha ; Karlsson, Pall ; Kristensen, Alexander G ; Krøigård, Thomas ; Jensen, Troels S ; Tankisi, Hatice ; Sindrup, Søren H ; Finnerup, Nanna B ; Gylfadottir, Sandra Sif</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c186t-c69401bcad54f1ac95d5e8decb936a3bca78752d11cc8c2677d288eb3ce00ee13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Cohort Studies</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Diabetic Neuropathies - epidemiology</topic><topic>Diabetic Neuropathies - pathology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glycated Hemoglobin - metabolism</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neural Conduction - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brask-Thomsen, Peter Kolind</creatorcontrib><creatorcontrib>Itani, Mustapha</creatorcontrib><creatorcontrib>Karlsson, Pall</creatorcontrib><creatorcontrib>Kristensen, Alexander G</creatorcontrib><creatorcontrib>Krøigård, Thomas</creatorcontrib><creatorcontrib>Jensen, Troels S</creatorcontrib><creatorcontrib>Tankisi, Hatice</creatorcontrib><creatorcontrib>Sindrup, Søren H</creatorcontrib><creatorcontrib>Finnerup, Nanna B</creatorcontrib><creatorcontrib>Gylfadottir, Sandra Sif</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brask-Thomsen, Peter Kolind</au><au>Itani, Mustapha</au><au>Karlsson, Pall</au><au>Kristensen, Alexander G</au><au>Krøigård, Thomas</au><au>Jensen, Troels S</au><au>Tankisi, Hatice</au><au>Sindrup, Søren H</au><au>Finnerup, Nanna B</au><au>Gylfadottir, Sandra Sif</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and Progression of Polyneuropathy Over 5 Years in Patients With Type 2 Diabetes</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2024-08-13</date><risdate>2024</risdate><volume>103</volume><issue>3</issue><spage>e209652</spage><pages>e209652-</pages><issn>0028-3878</issn><issn>1526-632X</issn><eissn>1526-632X</eissn><abstract>There is a need for knowledge regarding the natural course of diabetic polyneuropathy (DPN), a complication in type 2 diabetes (T2D). The aim of this study was to examine the development of DPN over time.
Patients with newly diagnosed T2D, recruited from a national cohort, and controls without diabetes of similar age and sex, underwent sensory phenotyping in 2016-2018. The Toronto consensus criteria were used to classify patients into possible, probable, and confirmed DPN. For this 5-year, observational, follow-up, cohort study, all participants were invited to a reexamination combining bedside sensory examination, quantitative sensory testing (QST), nerve conduction studies (NCSs), and skin biopsies measuring intraepidermal nerve fiber density (IENFD) in order to compare phenotypic and diagnostic changes over time.
Of the baseline 389 patients and 97 controls, 184 patients (median [interquartile range] diabetes duration 5.9 [4.1-7.4] years, mean hemoglobin A1c [HbA1c] 51 ± 11 mmol/mol at baseline) and 43 controls completed follow-up (46.9%). Confirmed DPN was present in 35.8% and 50.3%, probable DPN in 27.2% and 14.6%, possible DPN in 17.2% and 16.6%, and no DPN in 15.2% and 17.9% at baseline and follow-up, respectively. The estimated prevalence (95% CI) of confirmed DPN was 33.5% (24.9-42.1) compared with 22.7% (17.5-28.0) at baseline. During the follow-up period, 43.9% of patients with probable DPN developed confirmed DPN. Progression of neuropathy occurred in 16.5% and 24.7% and regression in 5.9% and 18.6% of patients based on NCS and IENFD, respectively. Progression based on NCS and/or IENFD was associated with higher baseline waist circumference and triglycerides, and regression with lower baseline HbA1c. Patients with at least probable DPN at baseline but neither patients without DPN nor controls developed increased spread of hyposensitivity, more hyposensitivity on QST and lower NCS
-scores at follow-up, and worsening of nerve parameters at follow-up correlated with higher baseline triglycerides.
In patients with well-regulated T2D, the proportion of patients with confirmed DPN increased over 5 years driven by progression from probable DPN. A large proportion of patients progressed, and a smaller proportion regressed on nerve parameters. Higher triglycerides correlated with this progression and may constitute a risk factor.</abstract><cop>United States</cop><pmid>39008800</pmid><doi>10.1212/WNL.0000000000209652</doi><orcidid>https://orcid.org/0000-0003-0357-8628</orcidid><orcidid>https://orcid.org/0000-0002-8323-1394</orcidid><orcidid>https://orcid.org/0000-0001-7082-9576</orcidid><orcidid>https://orcid.org/0000-0002-3487-6380</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-3878 |
ispartof | Neurology, 2024-08, Vol.103 (3), p.e209652 |
issn | 0028-3878 1526-632X 1526-632X |
language | eng |
recordid | cdi_proquest_miscellaneous_3081289505 |
source | MEDLINE; Journals@Ovid Complete; Alma/SFX Local Collection |
subjects | Aged Cohort Studies Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - epidemiology Diabetic Neuropathies - epidemiology Diabetic Neuropathies - pathology Disease Progression Female Follow-Up Studies Glycated Hemoglobin - metabolism Humans Male Middle Aged Neural Conduction - physiology |
title | Development and Progression of Polyneuropathy Over 5 Years in Patients With Type 2 Diabetes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T00%3A46%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20Progression%20of%20Polyneuropathy%20Over%205%20Years%20in%20Patients%20With%20Type%202%20Diabetes&rft.jtitle=Neurology&rft.au=Brask-Thomsen,%20Peter%20Kolind&rft.date=2024-08-13&rft.volume=103&rft.issue=3&rft.spage=e209652&rft.pages=e209652-&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000209652&rft_dat=%3Cproquest_cross%3E3081289505%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3081289505&rft_id=info:pmid/39008800&rfr_iscdi=true |